Ozempic maker struggles as it loses ground to rivals in weight-loss market
Novo Nordisk cuts sales and profit forecasts as it continues to lose ground to Mounjaro firm Eli Lilly The maker of Ozempic and Wegovy has cut its sales and profit forecasts as it continues to fall behind in the competitive market for obesity and diabetes treatments. Novo Nordisk’s chief (…)
Site référencé:
The Guardian (South&CentralAsia)
2847.jpg?width=140&quality=85&auto=format&fit=max&s=6294b6e1775d2a17950bf012b978e85a, 2847.jpg?width=460&quality=85&auto=format&fit=max&s=8d07e42f8ba690d3879851340f11f6eb, 2847.jpg?width=700&quality=85&auto=format&fit=max&s=0e2d0a82e6ad2e53e2b962b0aa290d0a
The Guardian (South&CentralAsia)
The grace period is over – so what now for Kemi Badenoch, the ‘not Robert Jenrick’ Tory leader ? | Henry Hill
5/11/2025
Intensive livestock farms fail to declare climate impacts in ‘emissions scandal’
5/11/2025
Global stock markets fall sharply over AI bubble fears
5/11/2025
Facebook’s job ads algorithm is sexist, French equality watchdog rules
5/11/2025
Bibi Rukiya’s Restless Daughter review – Lorca’s matriarch sparks tragic dance of desire
5/11/2025
In his first term, Donald Trump called journalists the enemy. This time around, he’s treating us like one | Betsy Reed
5/11/2025